Phrixus Pharmaceuticals announces Phase 2 clinical trial of Poloxamer 188 NF in non-ambulatory patients with Duchenne muscular dystrophy
September 14, 2017 08:00 ET
|
Phrixus Pharmaceuticals, Inc.
ANN ARBOR, Mich., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Phrixus Pharmaceuticals, Inc. (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy (DMD) and heart failure, today...
Phrixus Pharmaceuticals announces the first patient with Duchenne muscular dystrophy (DMD) to meet the 15-month mark on Carmeseal-MD™ (Poloxamer 188 NF)
September 13, 2017 09:00 ET
|
Phrixus Pharmaceuticals, Inc.
ANN ARBOR, Mich., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Phrixus Pharmaceuticals, Inc. (“Phrixus”), a company focused on therapies for Duchenne muscular dystrophy and heart failure, today announced that...
FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
September 07, 2016 08:00 ET
|
Phrixus Pharmaceuticals, Inc.
ANN ARBOR, Mich., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Phrixus Pharmaceuticals is announcing that FDA allowed Phrixus’s IND for Carmeseal-MD (P-188 NF) in Duchenne muscular dystrophy (DMD). The...